New hope for lung cancer patients deemed 'Untreatable'
NCT ID NCT04765709
Summary
This study tested a three-step treatment for patients with a large, inoperable form of lung cancer who cannot receive the standard therapy. The goal was to see if starting with a drug called durvalumab plus chemotherapy could shrink tumors enough for patients to safely receive follow-up radiation and more durvalumab. Researchers hoped this approach would help control the cancer and allow more people to get potentially effective treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER (STAGE III) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133, Italy
-
Gustave Roussy Institute
Paris, France
-
Vall d'Hebron Barcelona Hospital
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.